Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis

Curr Oncol. 2024 Nov 20;31(11):7390-7402. doi: 10.3390/curroncol31110545.

Abstract

Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death induced by ROS and inhibited by antioxidants such as cysteine, glutathione (GSH), and glutathione peroxidase 4 (GPx4). However, the link between αvβ3 expression, ferroptosis inhibition, and sensitivity to radiotherapy remains unclear. We showed that irradiated β3_KO medulloblastoma cells primarily die by ferroptosis, with β3-subunit expression correlating with radiotherapy sensitivity and anti-ferroptotic protein levels. Our findings suggest that integrin-αvβ3 signaling boosts oxidative stress resilience via mTORC1. Thus, targeting integrin-αvβ3 could enhance radiotherapy efficacy in medulloblastoma by inducing ferroptotic cell death.

Keywords: cilengitide; ferroptosis; integrin-αvβ3; medulloblastoma; radiotherapy.

MeSH terms

  • Cell Line, Tumor
  • Cerebellar Neoplasms* / radiotherapy
  • Ferroptosis* / drug effects
  • Humans
  • Integrin alphaVbeta3* / metabolism
  • Medulloblastoma* / drug therapy
  • Medulloblastoma* / radiotherapy

Substances

  • Integrin alphaVbeta3

Grants and funding

This research was funded by the Government of the Principality of Monaco, Fondation Flavien, AS Monaco FC, and Groupement des Entreprises Monégasques dans la Lutte contre le Cancer (GEMLUC).